<unk>  (trade name Zepatier ) is a fixed-dose combination for the treatment of hepatitis C, containing<unk>  (an inhibitor of hepatitis C virus's NS5A protein) and<unk>  (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients. Both<unk>  and<unk>  were developed by Merck & Co. The US Food and Drug Administration (FDA) approved the drug on 28 January 2016.
Elbasvir/grazoprevir
Atazanavir/cobicistat
Atazanavir/ritonavir
Darunavir/cobicistat
Ombitasvir/paritaprevir/ritonavir
Nirmatrelvir/ritonavir
Cabotegravir/rilpivirine
Abacavir/lamivudine